### Analysis

The earnings call for Merck & Co., Inc. highlights a mixed bag of results, with some positive signals and some challenges. The company reported strong sales growth in diabetes, hospital, acute care, vaccines, and animal health, while also noting the impact of divestitures and competition in certain markets. The company also mentioned the successful launch of KEYTRUDA and the potential for future launches. The guidance for 2015 projects revenue between $38.3 billion and $39.8 billion, with EPS expected to be in the range of $3.32 to $3.47. The company also mentioned its commitment to returning cash to shareholders and its focus on innovation.

### Short-Term Implications

#### Positive Factors:
1. **Sales Growth**: The company reported strong sales growth in key areas, which suggests that the business is performing well.
2. **Innovation**: The company’s focus on innovation and its pipeline of new products are promising.
3. **Shareholder Returns**: The company’s commitment to returning cash to shareholders is positive.

#### Negative Factors:
1. **Divestitures and Competition**: The company mentioned the impact of divestitures and competition in certain markets, which could affect future growth.
2. **Uncertainty in Hepatitis C Market**: The company mentioned the potential for increased competition in the hepatitis C market, which could impact pricing and access.
3. **Foreign Exchange Impact**: The strengthening of the U.S. dollar could negatively impact revenue and EPS.

### Conclusion

Given the mixed signals and the potential challenges, the short-term impact on the stock price is likely to be neutral. The company’s strong sales growth and focus on innovation are positive, but the uncertainty in certain markets and the potential impact of foreign exchange could offset these positives. Therefore, the stock price is likely to remain stable in the short term.

**Rating: 0**